Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02281773 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 518
- Enrollment target
NCT02281773 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 518 participants.
The verdict
NCT02281773, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 518 participants
- Enrollment target
Study Summary
The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
Interventions
- DRUG Placebo
- DRUG BI 409306 100 mg QD
- DRUG BI 498306 50 mg QD
- DRUG BI 498306 25 mg QD
- DRUG BI 409306 10 mg QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2014-11-10 |
| Est. Completion | 2016-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02281773
The ClinicalTrials.gov registry entry for NCT02281773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02281773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02281773 about?
NCT02281773 is a clinical study titled "A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.". The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
What is the current status of trial NCT02281773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 518 participants. The study started on 2014-11-10. Estimated completion is 2016-06-13.
What interventions are being tested in trial NCT02281773?
The interventions under investigation include: Placebo (DRUG), BI 409306 100 mg QD (DRUG), BI 498306 50 mg QD (DRUG), BI 498306 25 mg QD (DRUG), BI 409306 10 mg QD (DRUG).
Who is sponsoring clinical trial NCT02281773?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.